14 High Growth Dividend Paying Stocks to Invest In Now

8. Johnson & Johnson (NYSE:JNJ)

On March 17, HSBC analyst Morten Herholdt raised the firm’s price recommendation on Johnson & Johnson (NYSE:JNJ) to $280 from $265. It reiterated a Buy rating on the shares. The firm pointed to the current macro environment, noting that uncertainty, rising geopolitical risks, and lower exposure to AI disruption could draw investors toward healthcare and support outperformance in the near term.

On March 18, Reuters reported that the US Food and Drug Administration approved Johnson & Johnson’s oral pill for psoriasis. The approval gives patients a more convenient treatment option for the chronic autoimmune condition, which causes itchy, scaly, and inflamed skin. The drug is approved for moderate-to-severe plaque psoriasis in adults and children aged 12 and older who weigh at least 40 kg. The company did not respond to Reuters’ request for comment on pricing and availability.

The oral treatment, branded as Icotyde, is the first of its kind. It is expected to help Johnson & Johnson expand its presence in the psoriasis market and compete with existing treatments such as Bristol Myers Squibb’s Sotyktu and AbbVie’s Skyrizi. Wall Street analysts have said Icotyde has “blockbuster potential” as a safe and effective oral option. They also noted that a once-daily pill could take share from injectable treatments like Skyrizi and the company’s own Tremfya.

Johnson & Johnson (NYSE:JNJ) operates across a broad range of healthcare products. Its business is organized into two segments: Innovative Medicine and MedTech.